Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 1,543 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Women-Only Clear all
Completed Phase 2 Interventional Results available

A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer

NCT02747004
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Abemaciclib, Tamoxifen, Prophylactic Loperamide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
5
States / cities
Tucson, Arizona • Lebanon, New Hampshire • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 3:21 AM EDT
Not listed Not applicable Interventional

A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.

NCT01792726
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Boost to the tumour bed
Radiation
Lead sponsor
University College, London
Other
Eligibility
Female only
Enrollment
1,796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
8
States / cities
Los Angeles, California • Savannah, Georgia • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2019 · Synced Oct 20, 2026, 3:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117

NCT03325595
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AEF0117, Placebo
Drug
Lead sponsor
Aelis Farma
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 20, 2026, 3:21 AM EDT
Completed Not applicable Interventional

Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer

NCT00103181
View directory record Official record
Conditions
Breast Cancer
Interventions
3-dimensional conformal accelerated partial breast irradiation, brachytherapy, whole breast irradiation, MammoSite or other single-entry intracavitary device
Radiation
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
4,216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
374
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 295 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 20, 2026, 3:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants

NCT06820307
View directory record Official record
Conditions
Pain
Interventions
Suzetrigine, DRSP/EE, NGM/EE
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 20, 2026, 3:21 AM EDT
Completed Phase 2 Interventional

FP-101 for the Treatment of Hot Flashes in Postmenopausal Women

NCT03285672
View directory record Official record
Conditions
Hot Flashes
Interventions
FP-101, Placebo Comparator
Drug
Lead sponsor
Fervent Pharmaceuticals
Industry
Eligibility
40 Years and older · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
12
States / cities
Champaign, Illinois • Cary, North Carolina • Charlotte, North Carolina + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Oct 20, 2026, 3:21 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

NCT03610581
View directory record Official record
Conditions
Human Papillomavirus Infections
Interventions
Ad26.HPV16, Ad26.HPV18, MVA.HPV16/18, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Doral, Florida • Fort Myers, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 20, 2026, 3:21 AM EDT
Recruiting Phase 3 Interventional

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

NCT05281471
View directory record Official record
Conditions
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma
Interventions
olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar)
Biological · Drug
Lead sponsor
Genelux Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
33
States / cities
Mobile, Alabama • Tucson, Arizona • Duarte, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 20, 2026, 3:21 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

GSK706769 A First Time in Human Study For Males and Females

NCT00539201
View directory record Official record
Conditions
Healthy Subjects
Interventions
GSK706769
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 19, 2010 · Synced Oct 20, 2026, 3:21 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Neoadjuvant in Inflammatory Breast Cancer

NCT00756470
View directory record Official record
Conditions
Breast Cancer
Interventions
Lapatinib, Paclitaxel, 5-Fluorouracil (5-FU), Epirubicin, Cyclophosphamide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2014 · Synced Oct 20, 2026, 3:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Challenge! Adolescent Obesity Prevention

NCT03103269
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Challenge! Small Group Intervention, Challenge! Environmental Intervention
Behavioral · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
10 Years and older
Enrollment
789 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2019 · Synced Oct 20, 2026, 3:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran

NCT03973047
View directory record Official record
Conditions
Nausea
Interventions
Bremelanotide, Zofran, Placebo
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 20, 2026, 3:21 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

NCT00929006
View directory record Official record
Conditions
Puberty, Hyperandrogenism
Interventions
Micronized progesterone suspension, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 17 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 20, 2026, 3:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants

NCT06342700
View directory record Official record
Conditions
Autoimmune Disorder, Healthy Volunteers
Interventions
Rilzabrutinib crystalline form, Rilzabrutinib amorphous form
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 20, 2026, 3:21 AM EDT
Terminated Phase 3 Interventional

Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer

NCT00083993
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
Temsirolimus (CCI-779) for 34 months, Letrozole for 34 months
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
112
States / cities
Hoover, Alabama • Huntsville, Alabama • Tucson, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2011 · Synced Oct 20, 2026, 3:21 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of Adult Healthy Participants

NCT05475821
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-990, Placebo for ABBV-990
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 20, 2026, 3:21 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Kentucky Women's Justice Community Overdose Innovation Network - Phase II

NCT07179614
View directory record Official record
Conditions
Overdose Risk, Opioid Use Disorder, Stimulant Use Disorders
Interventions
Overdose Prevention Intervention Package (OPIP)
Behavioral
Lead sponsor
Michele Staton
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
3
States / cities
Barbourville, Kentucky • Harlan, Kentucky • Hyden, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 20, 2026, 3:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects

NCT03613649
View directory record Official record
Conditions
Electrocardiogram Repolarisation Abnormality, Gonococcal Infection
Interventions
AZD0914, Moxifloxacin, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 20, 2026, 3:21 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Comparative Bioavailability Study of TAH3311 5 mg Oral Dissolving Film vs ELIQUIS® 5 mg Tablet in Healthy Volunteers

NCT05995119
View directory record Official record
Conditions
Healthy Volunteers, Fasting, Fed
Interventions
Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®)
Drug
Lead sponsor
TAHO Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 20, 2026, 3:21 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Galactagogue Use in Lactating Women With Low Milk Supply

NCT05398367
View directory record Official record
Conditions
Breast Milk Expression
Interventions
Galactagogue Supplement for Treatment of Low Milk Supply
Dietary Supplement
Lead sponsor
Winthrop University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rock Hill, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 20, 2026, 3:21 AM EDT
Completed No phase listed Observational

Study of Pregnancy Regulation of Insulin and Glucose

NCT02763267
View directory record Official record
Conditions
Gestational Diabetes Mellitus
Interventions
Oral glucose tolerance test
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 20, 2026, 3:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Developing and Examining Evidenced-Based HIV Testing Messages

NCT03433053
View directory record Official record
Conditions
HIV/AIDS
Interventions
HIV Testing Message Intervention, Control
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 24 Years · Female only
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 20, 2026, 3:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of SRX251 Capsules in Healthy Female Volunteers

NCT00461370
View directory record Official record
Conditions
Healthy
Interventions
SRX251
Drug
Lead sponsor
Azevan Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 13, 2008 · Synced Oct 20, 2026, 3:21 AM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

The Effects of Aging and Estrogen on the Pituitary

NCT00386022
View directory record Official record
Conditions
Healthy
Interventions
GnRH, NAL-GLU GnRH antagonist, Estrogen patch
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years to 80 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 20, 2026, 3:21 AM EDT